Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase EARLY_PHASE1 1Phase 3 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 10Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 6Carcinoma, Transitional Cell 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Carcinoma, Renal Cell 5Breast Neoplasms 4Triple Negative Breast Neoplasms 3Recurrence 3Melanoma 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Sarcoma 2Lymphoma, Follicular 2Lymphoma 2Central Nervous System Neoplasms 2Uveal Melanoma 1Urethral Neoplasms 1Ureteral Neoplasms 1Solid Tumors 1Skin Neoplasms 1Sezary Syndrome 1Prostatic Neoplasms 1Primary Myelofibrosis 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Mycosis Fungoides 1Metastatic Urothelial Cell Cancer 1Metastatic Solid Tumors 1

Interventions

Cisplatin 35pembrolizumab 29Radiotherapy 26Cetuximab 26Docetaxel 17Paclitaxel 13Fluorouracil 13Cyclophosphamide 12fludarabine 11Radiotherapy, Intensity-Modulated 11Nivolumab 10Carboplatin 9atezolizumab 7Radiation 7Gemcitabine 7Erlotinib Hydrochloride 7Bortezomib 7fludarabine phosphate 6Pemetrexed 5Interleukin-2 5Radiosurgery 4Everolimus 4Drug Therapy 4Azacitidine 4olaparib 3motexafin gadolinium 3durvalumab 3cemiplimab 3Trastuzumab 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Head and Neck Neoplasms × avelumab × Clear all
NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
5 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡